Your browser doesn't support javascript.
loading
Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study
Arruda, L. K; Yang, A. C; Aoki, V; Criado, R. F. J; Pires, M. C; Lupi, O; Fabricio, L. H. Z; Richman, D; Silvi, S.
Affiliation
  • Arruda, L. K; University of São Paulo. Ribeirão Preto Medical School. Ribeirão Preto. Brazil
  • Yang, A. C; Disciplina de Imunologia Clínica e Alergia. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP). São Paulo. Brazil
  • Aoki, V; Departamento de Dermatologia. Hospital das Clínicas da Faculdade de Medicina da USP. São Paulo. Brazil
  • Criado, R. F. J; Faculdade de Medicina do ABC. São Paulo. Brazil
  • Pires, M. C; Hospital Padre Bento. Hospital do Servidor Público Estadual. São Paulo. Brazil
  • Lupi, O; Policlínica Geral do Rio de Janeiro (PGRJ). Universidade Federal do Estado do Rio de Janeiro (UNIRIO). Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro. Brazil
  • Fabricio, L. H. Z; Hospital Universitário Evangélico de Curitiba da Faculdade Evangélica do Paraná (HUEC/FEPAR). Paraná. Brazil
  • Richman, D; Sanofi Genzyme. Cambridge. USA
  • Silvi, S; Sanofi Genzyme. São Paulo. Brazil
J. investig. allergol. clin. immunol ; 31(3): 236-245, 2021. tab, graf
Article in English | IBECS | ID: ibc-215205
Responsible library: ES1.1
Localization: ES15.1 - BNCS
ABSTRACT

Background:

Atopic dermatitis is a chronic inflammatory skin disease with a prevalence of 0.02% to 8.1% in adults. Adult patients with moderate-to-severe atopic dermatitis are affected by frequent relapses and a significant disease burden.

Objective:

To determine the clinical, immunological, and therapeutic profile of Brazilian adults with atopic dermatitis.

Methods:

A multicenter, observational, retrospective, descriptive registry-based study was conducted at reference hospitals between December 2016 and October 2017. The data collected were demographics, personal and family history of atopic diseases, clinical manifestations, laboratory tests, disease severity and management.

Results:

Of the 187 patients included in the analysis, 56.1% were female and 71.7% were White, with a mean age of 24.7 years. Mean follow-up was 9 years. Asthma or other allergic diseases were reported by 80.2% of patients. The main comorbidity was hypertension (10.2%), and common disease manifestations included pruritus and erythema. Lesions generally affected flexural and nonflexural areas, with typical morphology. Around 83% of patients had moderate-to-severe disease, and 8.6% reported at least 1 hospitalization. Most patients received topical and/or systemic pharmacological therapies, including omalizumab (5.9%); 4.3% received phototherapy. Moreover, 66.8% of patients received adjuvant therapy, and 79.1% changed or discontinued treatment for atopic dermatitis due to remission (46.5%), poor effectiveness (33.7%), or lack of adherence (12.9%). Most patients presented characteristics of type 2 inflammation, with immunoglobulin E levels above 100 IU/mL (94.4%) and peripheral blood eosinophils above 5% (55.9%).

Conclusion:

Brazilian adult patients with severe atopic dermatitis need treatment to efficiently control the disease and improve quality of life (AU)
Subject(s)


Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Anti-Allergic Agents / Dermatitis, Atopic / Eosinophils / Omalizumab Limits: Adult / Female / Humans / Male Country/Region as subject: South America / Brazil Language: English Journal: J. investig. allergol. clin. immunol Year: 2021 Document type: Article Institution/Affiliation country: Departamento de Dermatologia/Brazil / Disciplina de Imunologia Clínica e Alergia/Brazil / Faculdade de Medicina do ABC/Brazil / Hospital Padre Bento/Brazil / FEPAR)+Brazil / Policlínica Geral do Rio de Janeiro (PGRJ)/Brazil / Sanofi Genzyme/Brazil / Sanofi Genzyme/USA / University of São Paulo/Brazil

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Anti-Allergic Agents / Dermatitis, Atopic / Eosinophils / Omalizumab Limits: Adult / Female / Humans / Male Country/Region as subject: South America / Brazil Language: English Journal: J. investig. allergol. clin. immunol Year: 2021 Document type: Article Institution/Affiliation country: Departamento de Dermatologia/Brazil / Disciplina de Imunologia Clínica e Alergia/Brazil / Faculdade de Medicina do ABC/Brazil / Hospital Padre Bento/Brazil / FEPAR)+Brazil / Policlínica Geral do Rio de Janeiro (PGRJ)/Brazil / Sanofi Genzyme/Brazil / Sanofi Genzyme/USA / University of São Paulo/Brazil
...